Compare SHASUN PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA DIVIS LABORATORIES SHASUN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 123.9 32.5 381.4% View Chart
P/BV x 8.5 7.3 116.5% View Chart
Dividend Yield % 0.2 0.6 38.1%  

Financials

 SHASUN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
DIVIS LABORATORIES
Mar-18
SHASUN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs941,142 8.3%   
Low Rs46533 8.6%   
Sales per share (Unadj.) Rs214.2146.6 146.1%  
Earnings per share (Unadj.) Rs5.333.0 16.2%  
Cash flow per share (Unadj.) Rs15.838.4 41.2%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %1.41.2 119.8%  
Book value per share (Unadj.) Rs53.3222.8 23.9%  
Shares outstanding (eoy) m56.62265.47 21.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.7 5.7%   
Avg P/E ratio x13.125.3 51.7%  
P/CF ratio (eoy) x4.421.8 20.3%  
Price / Book Value ratio x1.33.8 34.9%  
Dividend payout %18.730.3 61.9%   
Avg Mkt Cap Rs m3,958222,318 1.8%   
No. of employees `000NA10.8 0.0%   
Total wages/salary Rs m2,1644,561 47.4%   
Avg. sales/employee Rs ThNM3,616.0-  
Avg. wages/employee Rs ThNM423.8-  
Avg. net profit/employee Rs ThNM814.9-  
INCOME DATA
Net Sales Rs m12,12738,915 31.2%  
Other income Rs m2291,134 20.2%   
Total revenues Rs m12,35640,049 30.9%   
Gross profit Rs m1,00912,617 8.0%  
Depreciation Rs m5941,425 41.7%   
Interest Rs m41513 3,121.1%   
Profit before tax Rs m23012,313 1.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-733,543 -2.1%   
Profit after tax Rs m3028,770 3.4%  
Gross profit margin %8.332.4 25.7%  
Effective tax rate %-31.728.8 -110.0%   
Net profit margin %2.522.5 11.1%  
BALANCE SHEET DATA
Current assets Rs m6,88445,351 15.2%   
Current liabilities Rs m8,4566,507 129.9%   
Net working cap to sales %-13.099.8 -13.0%  
Current ratio x0.87.0 11.7%  
Inventory Days Days62127 48.6%  
Debtors Days Days10895 113.0%  
Net fixed assets Rs m4,97021,160 23.5%   
Share capital Rs m113531 21.3%   
"Free" reserves Rs m2,87558,625 4.9%   
Net worth Rs m3,02059,156 5.1%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34767,832 19.7%  
Interest coverage x1.6926.8 0.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.90.6 158.4%   
Return on assets %5.412.9 41.5%  
Return on equity %10.014.8 67.5%  
Return on capital %13.320.8 63.9%  
Exports to sales %46.40-   
Imports to sales %14.221.8 65.3%   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,7288,485 20.4%   
Fx inflow Rs m5,84332,359 18.1%   
Fx outflow Rs m2,1739,042 24.0%   
Net fx Rs m3,66923,317 15.7%   
CASH FLOW
From Operations Rs m3987,759 5.1%  
From Investments Rs m-1,635-4,783 34.2%  
From Financial Activity Rs m1,309-3,142 -41.7%  
Net Cashflow Rs m71-166 -42.9%  

Share Holding

Indian Promoters % 39.2 52.0 75.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 11.8 30.5%  
FIIs % 17.6 19.0 92.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 17.2 230.2%  
Shareholders   20,750 31,796 65.3%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Over 100 Points Down; Banking and IT Stocks Under Pressure(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.9% while the Hang Seng is also down 0.9%.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY19); Net Profit Up 68.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 68.9% YoY). Sales on the other hand came in at Rs 13 bn (up 29.4% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA - PROCTER & GAMBLE HEALTH COMPARISON

COMPARE SHASUN PHARMA WITH

MARKET STATS